RxDoctor Payments Data

Christopher Comeau

Family Medicine · Ogdensburg, NYNPI 1184633273

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 238 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AstraZeneca at 26.8% of the total. Reporting peaked in 2019 at $1,318 and has fallen 99.0% since, to $13 in 2022.

$3,786in general payments, 2019–2025

Across 238 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Boehringer Ingelheim$532
  • Novo Nordisk$362
  • GSK$361
  • Lilly USA, LLC$289
  • Novartis$235
  • plus $993 from 14 others

What the payments were for

  • Food & beverage$3,780100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,786 in reported general payments places this provider in the 85th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York →

Other family medicine in Ogdensburg

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →